Xeris Biopharma Holdings (XERS) Other Non-Current Liabilities (2021 - 2026)

Xeris Biopharma Holdings' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 68.12% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (up 68.12% YoY) and the FY2025 annual result came in at $8.4 million, up 326.94% from the prior year.
• Other Non-Current Liabilities was $8.1 million for Q1 2026 at Xeris Biopharma Holdings, down from $8.4 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $30.2 million in Q2 2022 and bottomed at $31000.0 in Q1 2023.
• A 5-year average of $7.6 million and a median of $5.5 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities plunged 85.51% — and 2024, when it soared 19461.29%.
• Xeris Biopharma Holdings' Other Non-Current Liabilities stood at $25.7 million in 2022, then slumped by 81.13% to $4.8 million in 2023, then plunged by 59.43% to $2.0 million in 2024, then jumped by 326.94% to $8.4 million in 2025, then fell by 3.23% to $8.1 million in 2026.
• Business Quant data shows XERS's Other Non-Current Liabilities at $8.1 million in Q1 2026, $8.4 million in Q4 2025, and $3.4 million in Q3 2025.